《一级预防抗栓现状和未来》由会员分享，可在线阅读，更多相关《一级预防抗栓现状和未来（35页珍藏版）》请在金锄头文库上搜索。
1、Antithombosis in Primary Prevention Where do we stand/where are we going Dr. Carlos Brotons Primary prevention trials with Aspirin: review of the Evidence 1988 British Doctors Trial 1998 Thrombosis Prevention Trial 1998 Hypertension Optimal Treatment (HOT) Study 1989 Physicians Health Study 2001 Pri
2、mary Prevention Project 2005 Womens Health Study Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin Alfred A. Bartolucci, PhD*, and George Howard, DrPH Am J Cardiol 2006; 98:746 Aspirin in the primary prevention of cardiovascular (CV) events TrialPati
3、ent populationAge range (years) Aspirin dosage BDT (1988)1Apparently healthy male physicians (n=5,139) 5078 500mg/day PHS (1989)2Apparently healthy male physicians (n=22,071) 4084 325mg qod HOT study (1998)3 Men and women with DBP 100115mmHg (n=18,790) 5080 75mg/day TPT (1998)4Men at high risk of he
4、art disease (n=5,499) 456975mg/day PPP (2001)5Men and women with 1 major CV risk factor (n=4,495) 5080+100mg/day WHS (2005)6Apparently healthy women (n=39,876) 45100mg qod BDT, British Doctors Trial; HOT, Hypertension Optimal Treatment; PHS, Physicians Health Study; PPP, Primary Prevention Project;
5、qod, every other day; TPT, Thrombosis Prevention Trial; WHS, Womens Health Study. 1. Peto R, et al. BMJ 1988;296:3136; 2. Physicians Health Study. N Engl J Med 1989;321:18258; 3. Hansson L, et al. Lancet 1998;351:175562. 4. The Medical Research Councils General Practice Research Framework. Lancet 19
6、98;351: 23341; 5. de Gaetano G, et al. Lancet 2001;357:8995. 6. Ridker PM, et al. N Engl J Med 2005;352:1293304. Primary findings (total CV events) from the six key trials Study Name Risk Aspirin Control/ Placebo Odds BDTLow 260/3429127/17101.0230.842 PHSLow 292/11037390/110340.7690.001 TPTHigh 208/
7、1268250/12720.7410.003 HOTLow 243/9399290/93910.8240.033 PPPLow 46/222665/22690.5460.006 WHSLow 539/19934585/199420.9820.780 TOTAL 1588/472931707/456180.86910% over 10 years) once blood pressure has been controlled (as closely as possible to the goal of less than 140/90 mmHg) In lower risk individua
8、ls a small absolute vascular benefit by aspirin maybe offset by the slightly greater absolute risk of bleeding complications EJCPR 2007;vol 14(suppl 2):S1-S113 American Heart Association (AHA) Guidelines Benefits of reducing CV risk outweigh these risks in most patients with higher coronary risk Dos
9、es of aspirin 75160 mg per day are as effective as higher doses Consider aspirin 75160 mg per day for people at higher risk (especially those with a 10-year CHD risk of 10 percent or greater) Circulation 2002;106:338-391 AHA guidelines for CVD prevention in women (2007 update) Aspirin: high-risk Any
10、 vascular disease, end-stage or chronic renal disease, diabetes mellitus, and 10-year Framingham risk 20% Aspirin therapy 75 to 325 mg per day should be used in high-risk women unless contraindicated (Class I, Level A) Circulation 2007;115:1481-1501 Guide to clinical preventive services 2008: recomm
11、endations from USPSTF USPSTF strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for CHD Discussions with patients should address both the potential benefits and harms of aspirin therapy Grade: A Recommendation Guide to clinical preventive servic
12、es 2008: recommendations from USPSTF Baseline risk for CHD over 5 years: 1% Total mortality: no effect CHD events: 14 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Guide to clinical preventive services 2008: recommendations from USPSTF Baseline risk for CHD
13、 over 5 years: 3% Total mortality: no effect CHD events: 412 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Guide to clinical preventive services 2008: recommendations from USPSTF Baseline risk for CHD over 5 years: 5% Total mortality: no effect CHD events:
14、620 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Who should be treated with aspirin? The decision to use aspirin should be based on a balance of the risks and benefits for each person taking into account their absolute risk for CHD or CVD. Patients with es
15、tablished CVD or very high risk patients should be treated with aspirin unless contraindicated. Before starting treatment with aspirin always consider risks factors for GI bleeding such as age and concomitant use of NSAIDS. An unanswered question In primary prevention is whether the benefits of dail
16、y aspirin outweights the harms in specific populations (such as those with moderate risk of CHD) Antithombosis in Primary Prevention Where are we going ? Ongoing trials to assess the benefit:risk profile of low-dose aspirin in the prevention of first CV events The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) Rationale ARRIVE will expand the alrea
